原发性激素受体阴性HER2阳性乳腺癌与三阴性乳腺癌的肿瘤免疫微环境比较
Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer.
作者信息
Vos Hanne, Lambein Kathleen, Richard François, Mariën Bram, Nevelsteen Ines, Punie Kevin, Wildiers Hans, Berben Lieze, Laenen Annouschka, Floris Giuseppe, Desmedt Christine, Smeets Ann
机构信息
Department of Surgical Oncology, University Hospitals Leuven; Department of Oncology, KU Leuven, Leuven, Belgium.
Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
出版信息
NPJ Breast Cancer. 2021 Sep 23;7(1):128. doi: 10.1038/s41523-021-00332-7.
The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cancer based on a selection of immune markers at the protein level in an institutional retrospective series. Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.
绝大多数针对乳腺癌患者免疫检查点抑制（ICI）的研究都集中在三阴性乳腺癌（TNBC）上。在本研究中，我们在一项机构回顾性系列研究中，基于蛋白质水平上的一系列免疫标志物，比较了TNBC与激素受体阴性HER2阳性乳腺癌之间的肿瘤免疫微环境（TIME）。此外，我们使用公开可用的转录组学数据进行了类似的比较。总体而言，结果显示两组的TIME具有可比性，这可能对激素受体阴性HER2阳性乳腺肿瘤患者使用ICI具有启示意义。
Zotero 插件